Medium Half-Life Inorganic Radionuclides for Pet Imaging

  • Jamal Zweit
Chapter
Part of the Developments in Nuclear Medicine book series (DNUM, volume 30)

Abstract

In vivo radiotracer imaging continues to grow in importance and consideration is constantly given to the relative merits of the different techniques of radionuclide imaging and how they complement each other. The aim of this review is to highlight the role of inorganic medium-lived radionuclides within the field of Positron Emission Tomography (PET). PET has evolved around the use of short-lived radioactive tracers of natural organic elements such as 11C (20 min), 13N (10 min.) and 15O (2 min). Although fluorine is not a commonly natural constituent of organic molecules, 18F (110 min), as a hydrogen analogue, is the radionuclide most commonly used and 18F-FDG is currently the most widely used PET radiotracer. This is due at least in part to the longer half-life of 18F which offers both practical and technical advantages to study prolonged biochemical interactions that are not possible even with the longest half-life organic radionuclide (11C, 20 min.). This review therefore focuses on exploiting the use of medium half-life radionuclides in PET imaging. This expansion could aid in realising the true potential of PET by combining the sensitivity and quantitative accuracy of the technique with a large number of specific tracers developed for single photon imaging using for example, 99mTc, 123, 131I, 111In, 67Ga and 67Cu radionuclides. Here, the positron-emitters 94mTc, 120,124I, 66,68In, 66,68Ga and 61,64Cu could be used as the PET imaging analogues. The abundance of inorganic positron-emitting radionuclides span a wide range of half-lives (∼ 1–100 hours) and spectrum of chemical properties ranging from the alkali metals to transition elements to lanthanides and the halogens (although not strictly ’inorganic’ elements, the halogens are included for completion.

Keywords

Positron Emission Tomography Positron Emission Tomography Imaging Excitation Function Positron Emission Tomography Radiotracer Imaging Feasibility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Young, Camochan P, Trivedi M et al. Pharmacokinetics and biodistribution of radiolabeled idoxifene: prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy. Nucl Med Biol 1995; 22: 405–411.PubMedCrossRefGoogle Scholar
  2. 2.
    Lederer C M and Shirley V S. Table of isotopes. 7th ed. New York: John Wiley & Sons, Inc, 1977.Google Scholar
  3. 3.
    Sowby F D. Radionuclide transformations, energy and intensity of emissions. ICRP38. Oxford: Pergamon Press, 1983.Google Scholar
  4. 4.
    Nickles RJ. A shotgun approach to the chart of the nuclides. Acta Radiologica 1991; 376: 69–71.Google Scholar
  5. 5.
    Zweit JH. The production of medium half-life radionuclides for positron emission tomography [dissertation]. Manchester: Univ. of Manchester, 1989.Google Scholar
  6. 6.
    Ruth TJ, Pate BD, Robertson R, Porter JK. Radionuclide production for the biosciences. Nucl Med Biol 1989; 16: 323–336.Google Scholar
  7. 7.
    Qiam S M, Rosch F, Scholten B, Stocklin G, Kovacs Z, Trkanyi F. Nuclear data relevant to the production of medically important positron emitters Br-75, Y-86, Tc-94m and I-124. In: Dickens J K, editor, Proc. Int. Conf. on Nuclear Data for Science and Technology, 1994, Gatlinburg, Term.. American Nuclear Society.Google Scholar
  8. 8.
    Nickles RJ, Sunderland JJ. Low-energy cyclotrons: will they meet performance standards? In: Colman J, editor. Mosby Year Book. St Louis, Mosby Pub. Co., 1992: 95–100.Google Scholar
  9. 9.
    Cutler PD, Schwarz SW, Anderson CJ et al. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. J Nucl Med 1995; 36: 2363–2371.PubMedGoogle Scholar
  10. 10.
    Philpott GW, Schwarz SW, Anderson CJ et al. Radioimmuno PET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med 1995; 36: 1818–1824.PubMedGoogle Scholar
  11. 11.
    Wilson CB, Snook DE, Dhokia B et al. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124Iodine in patients with breast cancer. Int J Cancer 1991; 47: 344–347.PubMedCrossRefGoogle Scholar
  12. 12.
    Ott RJ, Tait D, Flower MA, Babich JW and Lambrecht RM. Treatment planning for 131U-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol 1992; 65: 787–791.PubMedCrossRefGoogle Scholar
  13. 13.
    Larson SM, Pentlow KS, Volkow ND et al. PET scanning of iodine-124–3F9 as an approach to tumor dosimetry during treatment planning for radio immunotherapy in a child with neuroblastoma. J Nucl Med 1992; 33: 2020–2023.PubMedGoogle Scholar
  14. 14.
    Daghighian F, Pentlow KS, Larson SM et al. Development of a method to measure kinetics of radiolabeled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eu J Nucl Med 1993; 20:402–409.Google Scholar
  15. 15.
    Flower MA, Al-Saadi A, Harmer CL, McCready VR, Ott RJ. Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy. Eu J Nucl Med 1994; 21: 531–536.Google Scholar
  16. 16.
    Visvikis D, Zweit J, Flower M, Camochan P, Ott RJ. 83Sr, a positron emitting radionuclide for dose estimation of 89Sr therapy: imaging feasibility using MUP-PET. Nucl Med Comm 1994; 15: 229 (abstract).CrossRefGoogle Scholar
  17. 17.
    Råsch F, Blessing G, Linse KH, Herzog H, Qaim SM. Production of the positron emitting strontium isotope Sr-83 and PET phantom measurements preparatory to the evaluation of Sr-89 pharmacokinetics and dosimetry. J Nucl Med 1996; 37:166P (abstract).Google Scholar
  18. 18.
    Marsden PK, Ott RJ, Bateman JE, Cherry SR, Flower MA, Webb S. The performance of a multiwire proportional chamber positron camera for clinical use. Phys Med Biol 1989; 34: 1043–1062.PubMedCrossRefGoogle Scholar
  19. 19.
    Glass D, Young H, Myers M et al. Comparison of a rotating, partial ring PET scanner (ECAT-ART) with a dual-headed gamma camera for whole-body imaging with Fe-52 transferrin. J Nucl Med 1996; 37: 148P (abstract).Google Scholar
  20. 20.
    Smith-Jones PM, Stolz B, Bruns C et al. Galhum-67/Gallium-68–[DFO]-octreotide — A potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and prehminary in vivo studies. J Nucl Med 1994; 35:317–325.PubMedGoogle Scholar
  21. 21.
    Zweit J, Downey S, Sharma H. A method for the production of iron-52 with a very low iron-55 contamination. Appl Radiat Isot 1988; 39: 1197–1201.CrossRefGoogle Scholar
  22. 22.
    Suzuki K. Production of Fe-52 using proton bombardment of natural manganese. Radioisotopes (Japan) 1985; 34: 537–542.Google Scholar
  23. 23.
    Smith-Jones P, Schwarzbach R, Weinreich R. The production of Fe-52 by means of a medium engergy proton accelerator. Radiochim Acta 1990; 50: 33–39.Google Scholar
  24. 24.
    Nieweg OE, Beekhuis H, Paans AMJ et al. Detection of lung cancer with 55Co-bleomycin using a positron camera. A comparison with 57Co-bleomycin and 55Co-bleomycin single photon scintigraphy. Eur J Nucl Med 1982; 7: 104–107.PubMedCrossRefGoogle Scholar
  25. 25.
    Vaalburg W. What is new in European PET Centres? EEC concerted action on PET investigations of cellular regeneration and degeneration newsletter 1994; 19:3.Google Scholar
  26. 26.
    Sharma H, Zweit J, Smith AM, Downey S. Production of cobalt-55, a short-lived positron emitting radiolabel for bleomycin. Appl Radiat Isot 1986; 37: 105–109.CrossRefGoogle Scholar
  27. 27.
    Maziere B, Stulzaft O, Verret JM, Comar D, Syrota A. Co-55 and Cu-64-DTPA: new radiopharmaceuticals for quantitative tomocisternography. Appl Radiat Isot 1983; 34: 595–598.CrossRefGoogle Scholar
  28. 28.
    Watanabe M, Nakahar H, Murakami Y. Production of Co-55 from helium-3 bombardment of natural manganese. Appl Radiat Isot 1979; 30: 625–629.CrossRefGoogle Scholar
  29. 29.
    Parker D, editor. Macrocycle synthesis. Oxford: Oxford University Press, 1996.Google Scholar
  30. 30.
    Zweit J, Foster C, Camochan P, Hall A, Parker D. Copper-64–13N4-macrocycle-biotin-conjugate: radiolabelling and radiotracer kinetic studies in rodents. J Nucl Med 1996; 37: 166P (abstract).Google Scholar
  31. 31.
    Zweit J, Camochan P, Goodall R and Ott RJ. Excitation functions of proton induced reactions on cobalt: production of no-carrier added nickel-57, a positron emitting label for doxorubicin.Google Scholar
  32. 32.
    Cotton FA, Wilkinson G. Advanced inorganic chemistry: a comprehensive text. 3rd ed. New York: John Wiley & Sons, 1972.Google Scholar
  33. 33.
    Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol, in press.Google Scholar
  34. 34.
    Muramatsu H, Shirai E, Nakahara H, Murakami Y. Alpha particle bombardment of natural nickel target for the production of 61Cu. Int J Appl Radiat Isot 1978; 29: 611–614.CrossRefGoogle Scholar
  35. 35.
    SzelecsÈnyi F, Blessing G, Qaim SM. Excitation functions of proton induced nuclear reactions on enriched 61Ni and 64Ni: possibility of production of no-carrier-added 61Cu and 64Cu at a small cyclotron. Appl Radiat Isot 1993; 44: 575–580.CrossRefGoogle Scholar
  36. 36.
    Anderson CJ, Connett JM, Schwarz SW et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992; 33: 1685–1691.PubMedGoogle Scholar
  37. 37.
    Shen S, DeNardo GL, DeNardo SJ et al. Dosimetric evaluation of copper-64 in copper-67–2IT-BAT-Lym-1 for radioimmunotherapy. J Nucl Med 1996; 37: 146–150.PubMedGoogle Scholar
  38. 38.
    Anderson CJ, Pajeau TS, Edwards B, Sherman ELC, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med 1995; 36: 2315–2325.PubMedGoogle Scholar
  39. 39.
    Zinn KR, Chaudhuri TR, Cheng T, Morris SJ, Meyer WA. Producton of no-carrier-added 64Cu from zinc metal irradiated under boron shielding. Cancer 1994; 73: 774–778.PubMedCrossRefGoogle Scholar
  40. 40.
    Zweit J, Smith AM, Downey S and Sharma HL. Excitation functions for deuteron induced reactions in natural nickel: production of no-carrier-added 64Cu from enriched 64Ni targets for positron emission tomography. Appl Radiat Isot 1991; 42:193–197.CrossRefGoogle Scholar
  41. 41.
    McCarthy DW, Shefer RE, Klinkowstein RE et al. The efficient production high specific activity copper-64 using a biomedical cyclotron. J Nucl Med 1996; 37: 61P (abstract).Google Scholar
  42. 42.
    Green MA, Welch MJ. Gallium radiopharmaceutical chemistry. Nucl Med Biol 1989; 16: 435–448.Google Scholar
  43. 43.
    Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan B J. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 1991; 27: 1356–1361.PubMedCrossRefGoogle Scholar
  44. 44.
    Zweit J, Sharma H, Downey S. Production of gallium-66, a short-lived positron emitting radionuclide. Appl Radiat Isot 1987; 38: 499–501.CrossRefGoogle Scholar
  45. 45.
    Goethals P, Coene M, Siegers G, Agon P, Deman J, Schelstraete K. Cyclotron production of carrier-free Ga-66 as a positron emitting label of albumin colloids for clinical use. Eur J Nucl Med 1988; 14: 152–154.PubMedCrossRefGoogle Scholar
  46. 46.
    Tarkanyi F, Szelecsenyi F, Kovacs Z. Excitation functions for proton induced reactions on enriched Zn-66, Zn-67 and Zn-68. Radiochimica Acta 1990; 50: 19–26.Google Scholar
  47. 47.
    Qaim SM. Recent developmnets in the production of F-18, Br-75, 76, 77 and 1-123. Appl Radiat Isot 1986; 37: 803–810.CrossRefGoogle Scholar
  48. 48.
    Wilbur DS. Radiohalogenation of proteins: An overview of radionuclides, labelling methods and reagents for conjugate labelling. Bioconjugate Chem 1992; 3: 433–470.CrossRefGoogle Scholar
  49. 49.
    Locíh CH, Mardon K, Valette H, et al. Preparation and pharmacological preparation of Br-76-metaobromobenzylguanidine (Br-76-MBBG). Nucl Med Biol 1994; 21: 49–55.CrossRefGoogle Scholar
  50. 50.
    Clerc J, Mardon K, Galons H et al. Assessing intratumour distribution and uptake with MBBG versus MIBG imaging and targeting xenografted PC12-pheochromocytoma cell line. J Nucl Med 1995; 36: 859–866.PubMedGoogle Scholar
  51. 51.
    Lovqvist A, Sundin A, Ahlstrom H, Carlsson J, Lundqvist H. Br-76-labelled monoclonal anti-CEA antibodies for radioimmuno-positron emission tomography. Nucl Med Biol 1995; 22: 125–131.PubMedCrossRefGoogle Scholar
  52. 52.
    Lundqvist H, Malmborg P, Langstrom B, Chiengmai SC. Simple production of Br-77-and 1–123-in the labelling of Br-77-BrUdR and I-123-IUdR. Appl Radiat Isot 1979; 30: 39–43.CrossRefGoogle Scholar
  53. 53.
    Zweit J, Flower MA, Visvikis D, Camochan P, Ott RJ. Strontium-83, a positron emitting radionuclide for dose estimation of strontium-89 therapy: production, biodistribution and preliminary imaging. Eur J Nucl Med 1993; 20: 862 (abstract).Google Scholar
  54. 54.
    Rosch F, Qaim SM, Stocklin G. Production of the positron emitting radioisotope Y-86 for Nuclear medical application. Appl Radiat Isot 1993; 44: 677–681.CrossRefGoogle Scholar
  55. 55.
    Herzog H, Rosch F, Stocklin G, Christoph L, Qaim SM, Feinendegen LE. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics. J Nucl Med 1993; 34: 2222–2226.PubMedGoogle Scholar
  56. 56.
    Lewellen TK, Krohn KA, Link JM, Eary JF. Feasibility Zr-89 as a PET imaging agent. Proc. the 72nd Scientific Assembly and Annual Meeting of the Radiological Society of North America; 1986, 70.(abstract).Google Scholar
  57. 57.
    Link JM, Krohn KA, Eary JF. Zr-89 for antibody labelling and positron emission tomography. J Lab Comp Radiopharm 1986; 23: 1297 (Abstract).Google Scholar
  58. 58.
    Dejesus OT and Nickles RJ. Production and purification of Zr-89, a potential PET antibody label. Appl Radiat Isot 1990; 41: 789–790.CrossRefGoogle Scholar
  59. 59.
    Zweit J, Downey S, Sharma H. Production of no-carrier added zirconium-89 for positron emission tomography. Appl Radiat Isot 1991; 42: 199–201.CrossRefGoogle Scholar
  60. 60.
    Meijs WE, Hercheid JDM, Haisma HJ et al. Production of highly pure no-carrier added Zr-89 for the labelling of antibodies with a positron emitter. Appl Radiat Isot 1994; 45: 1143–1147.CrossRefGoogle Scholar
  61. 61.
    Meijs WE, Haisma HJ, Klok RP et al. Production of Zr-89-labelled antibodies and their biodistribution in tumour-bearing mice. J Lab Comp Radiopharm 1995; 37: 560–562.Google Scholar
  62. 62.
    Nickles RJ, Nunn AD, Stone CK, Cristian BT. Technetium-94m-teboroxime: snthesis, dosimetry and clinical PET imaging studies. J Nucl Med 1993; 34: 1058–1066.PubMedGoogle Scholar
  63. 63.
    Christian BT, Nickles RJ, Stone CK, Mulnix TL, Clark J. Improving the radionuclidic purity of Tc-94m for PET imaging. Appl Radiat Isot 1995; 46: 69–73.CrossRefGoogle Scholar
  64. 64.
    Stone CK, Christian BT, Nickles RJ, Perlman SB. Technetium-94m-labelled methoxyisobutyl isonitrile: dosimetry and resting cardiac imaging with positron emission tomography. J Nucl Cardiology 1994; 1: 425–433.CrossRefGoogle Scholar
  65. 65.
    Rosch F and Qaim SM. Nuclear data relevant to the production of the positron emitting technetium isotope Tc-94m via the Mo-94(p,n) reaction. Radiochimica Acta 1993; 62: 115–121.Google Scholar
  66. 66.
    Denzler FO, Rosch F, Qaim SM. Excitation functions of alpha induced reactions on highly enriched Mo-92: comparative evealuation of production routes for Tc-94m. Radiochimica Acta 1995; 68: 13–20.Google Scholar
  67. 67.
    OíConnel MEA, Flower MA, Hinton PJ, Harmer CL, McCready VR. Radiation dose assessment in radioiodine therapy. Dose response relationships in differentiated thyroid carcinoma using quantitative scanning and PET. Radiother Oncol 1993; 28: 16–26.CrossRefGoogle Scholar
  68. 68.
    Bakir A, Eccles S, Babich J et al. c-erb2 protein overexpression in breast cancer as a target for PET using iodine-124 labelled monoclonal antibodies. J Nucl Med 1992; 33: 2154=-2160.PubMedGoogle Scholar
  69. 69.
    Zweit J, Bakir MA, Ott RJ, Sharma H, Cox M, Goodall R. Excitation functions of proton induced reactions in natural tellurium: production of no-carrier added 1–124 for PET applications. Proc. IV Int. Workshop on Targetry and Target Chemistry, 1991; Villigen, Switzerland, 76–78. (Weinreich R, ed.).Google Scholar
  70. 70.
    Scholten B, Kovacs Z, Tarkanyi F, Qaim SM. Excitation functions of Te-124(p,xn) 1–123, 124 reactions from 6 to 31 MeV with special reference to the production of 1–124 at a small cyclotron. Appl Radiat Isot 1995; 46: 255–259.CrossRefGoogle Scholar
  71. 71.
    Sharma H, Zweit J, Downey S, Smith AM, Smith AG. Production of 1–124 for positron emission tomography. J Lab Comp Radiopharm 1989; 26: 165–167.CrossRefGoogle Scholar
  72. 72.
    Lambrecht RM, Sajjad M, Qureshi MA, Al-Yanbawi SJ. Production of 1–124. J Radioanal Nucl Chem Letters 1988; 127: 143–150.CrossRefGoogle Scholar
  73. 73.
    Firouzbakht ML, Schlyer DJ, Finn RD, Laguzzi G, Wolf AP. Iodine-124 production: excitation functions for the Te-124(d,2n) and Te-124(d,3n) reactions from 7 to 24 MeV. Nucl Instr Meth 1993; B79: 909.Google Scholar
  74. 74.
    Zweit J, Luthra SK, Brady F, Camochan P, Ott RJ, Jones T. Iodine-120, a new positron emitting radionuclide for PET radiopharmaceuticals. J Lab Comp Radiopharm 1995; 37: 823–825.Google Scholar
  75. 75.
    Zweit J, Flower MA, Brown A et al. Iodine-120-mIBG: production and NCA labelling of a new PET radiotracer. J Nucl Med 1996: 37: 191p (abstract).Google Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • Jamal Zweit

There are no affiliations available

Personalised recommendations